Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $235.0 million.

  • Arcus Biosciences' Total Current Liabilities rose 930.23% to $235.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $235.0 million, marking a year-over-year increase of 930.23%. This contributed to the annual value of $226.0 million for FY2024, which is 2282.61% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Total Current Liabilities is $235.0 million, which was up 930.23% from $210.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Total Current Liabilities ranged from a high of $235.0 million in Q3 2025 and a low of $130.4 million during Q2 2021
  • In the last 5 years, Arcus Biosciences' Total Current Liabilities had a median value of $184.0 million in 2023 and averaged $183.7 million.
  • Over the last 5 years, Arcus Biosciences' Total Current Liabilities had its largest YoY gain of 52871.36% in 2021, and its largest YoY loss of 1228.27% in 2021.
  • Over the past 5 years, Arcus Biosciences' Total Current Liabilities (Quarter) stood at $166.0 million in 2021, then grew by 16.27% to $193.0 million in 2022, then decreased by 4.66% to $184.0 million in 2023, then rose by 22.83% to $226.0 million in 2024, then increased by 3.98% to $235.0 million in 2025.
  • Its last three reported values are $235.0 million in Q3 2025, $210.0 million for Q2 2025, and $192.0 million during Q1 2025.